论文部分内容阅读
[目的]观察纳米脂质体pORF-mCD40L结合化疗药物顺铂观察其在实验性腹水治疗中的作用。[方法]选用H22肝癌细胞注入KM小鼠腹腔来建立恶性腹水动物模型,各治疗组腹腔内注射药物观察腹水生长的不同抑制程度。[结果]治疗组较对照组腹膜渗透性明显降低,OD值比较显示对照组最大(0.852),联合治疗组最小(0.250),各组之间比较差异有统计学意义(P﹤0.05)。以流式细胞仪测定各组腹水肿瘤细胞凋亡,发现治疗各组(63.2%、56.1%、42.5%)与对照组(8.4%)比较差异均有统计学意义(P﹤0.01)。联合治疗组小鼠在腹水接种后d22时仍有60%小鼠存活,而对照组已无小鼠存活,至d42时联合治疗组仍有40%小鼠存活,表明联合治疗明显延长了腹水小鼠存活时间。[结论]治疗组较对照组有明显的抑制腹水生成的作用。
[Objective] To observe the effect of nano-liposome pORF-mCD40L combined with cisplatin in the treatment of experimental ascites. [Methods] H22 hepatoma cells were injected into the peritoneal cavity of KM mice to establish animal models of malignant ascites. The intraperitoneal injection of drugs in each treatment group was used to observe the different degrees of inhibition of ascites growth. [Results] The peritoneal permeability of the treated group was significantly lower than that of the control group. OD value showed the largest (0.852) in the control group and the lowest (0.250) in the combined treatment group. The difference between the two groups was statistically significant (P <0.05). Flow cytometry was used to detect the apoptosis of ascites tumor cells in each group. The results showed that there were significant differences between the treatment groups (63.2%, 56.1%, 42.5%) and the control group (8.4%) (P <0.01). In the combination therapy group, 60% of mice remained alive at d22 after ascites inoculation while no mice survived in the control group, and 40% of the mice in the combination therapy group survived by d42, indicating that the combined treatment significantly prolonged ascites Rat survival time. [Conclusion] Compared with the control group, the treatment group obviously inhibited the ascites production.